Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 6/20 | 0.98 |
| ▸ | HRH1 | P35367 | 4/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.98 |
| ▸ | USP2 | O75604 | 3/20 | 0.98 |
| ▸ | DRD2 | P14416 | 3/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.98 |
| ▸ | HRH2 | P25021 | 2/20 | 0.98 |
| ▸ | HTR2A | P28223 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | DRD4 | P21917 | 1/20 | 0.98 |
| ▸ | HTR7 | P34969 | 1/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.98 |
| ▸ | HTR5A | P47898 | 1/20 | 0.98 |
| ▸ | HTR6 | P50406 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etodroxizine SCHEMBL9064076 | 1.00 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL4491 | 0.99 | DRD3 (1.00) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL4492 | 0.99 | DRD3 (1.00) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL383277 | 0.99 | DRD3 (1.00) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL3061159 | 0.99 | DRD3 (1.00) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL491323 | 0.98 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL28290521 | 0.98 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL41450 | 0.98 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL41448 | 0.98 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL15532242 | 0.96 | DRD3 (0.95) | DRD3HRH1KCNH2CYP2D6USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141499-A1 | CARDIOSPHERE-DERIVED CELL (CDC) THERAPY FOR THE TREATMENT OF VIRAL INFECTIONS | CEDARS-SINAI MEDICAL CENTER | 2023-05-11 | — | — | US | claimed |
| EP-3973961-A1 | USE OF HYDROXYZINE AND ANTIHISTAMINE ANALOGS FOR TREATING THE COVID-19 DISEASE | ASSISTANCE PUBLIQUE, HOPITAUX DE PARIS (FR) | 2022-03-30 | — | — | EP | claimed |
| WO-2021188899-A1 | CARDIOSPHERE-DERIVED CELL (CDC) THERAPY FOR THE TREATMENT OF VIRAL INFECTIONS | CEDARS-SINAI MEDICAL CENTER (US) | 2021-09-23 | — | — | WO | claimed |
| US-9770514-B2 | Tamper-resistant pharmaceutical dosage forms | ExxPharma Therapeutics LLC (US) | 2017-09-26 | — | — | US | claimed |
| US-9757376-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20150064250-A1 | Tamper-Resistant Pharmaceutical Dosage Forms | ExxPharma Therapeutics LLC (US) | 2015-03-05 | — | — | US | claimed |
| US-8933013-B2 | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory | NONO INC. (CA) | 2015-01-13 | — | — | US | claimed |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | LOS ALAMOS NAT SECURITY LLC (US) | 2013-09-26 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20030204089-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | COSSEMENT ERIC (BE) | 2003-10-30 | — | — | US | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0955295-A1 | Therapeutically active levorotatory and dextrorotatory 1-((4-chlorophenyl)phenylmethyl) piperazines | UCB, S.A. (BE) | 1999-11-10 | — | — | EP | claimed |
| EP-0618796-B1 | ALLEVIATING OR PREVENTION OF MIGRAINE HEADACHE ONSET WITH MAST CELL DEGRANULATION BLOCKING AGENTS | KOS PHARMA INC (US) | 1999-05-06 | — | — | EP | claimed |
| EP-0341745-B1 | Crosslinked carboxy polysaccharides | FIDIA SPA (IT) | 1994-12-14 | — | — | EP | claimed |
| EP-0617028-A1 | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine | U C B, S.A. (BE) | 1994-09-28 | — | — | EP | claimed |
| US-5250529-A | Administering during prodrome phase in absence of analgesic | KOS PHARMACEUTICALS, INC. (US) | 1993-10-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030204089-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | RPLP1, QDPR, PRLHR | DRD3 448/4885HRH1 135/4885KCNH2 248/4885 |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | MCOLN1, PYM1, MCOLN2 | DRD3 2746/4885HRH1 2448/4885KCNH2 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.